| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Dermata Therapeutics, Inc.
$1.63
+0.21 (+14.79%)
D 26Pipeline Score Overvalued Pharma · Clinical
Market Cap
6.56 M
EPS
-2.08
P/E Ratio
-
Value Trade
28.95 K
13.99 %
Week
26.36 %
1 Month
32.52 %
3 Month
34.71 %
6 Month
-99.99 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
218.33 K
52 Week Range
0.95 - 6.22
% held by Insiders
32.71 %
% held by Institutions
3.05 %
Enterprise Value
2.14 M
Total Shares
4.02 M
Short %
1.87 %
Float Shares
3.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dermata Therapeutics, Inc.
127Total events
2Upcoming
23Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2022-12-01 | DMT310 (once-weekly topical) | Phase 2 topline data readout | Phase 2 | — | – | – | – |
2022-12-01 | DMT310 (once-weekly topical) | Phase 2 topline data readout | Phase 2 | — | – | – | – |
2022-12-01 | DMT310 (once-weekly topical) | Phase 2 topline data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $1M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 28%
Micro Cap (rank 673 of 933)
Percentile RankDermata Therapeutics, Inc. faces pipeline headwinds (26/100), with $767M risk-adjusted pipeline value, led by DMT310 in Acne Vulgaris (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT310 Small molecule | Acne Vulgaris | Phase 3 | NCT04106778 | 58% | $363M | COMPLETED | 822 | - | - | May 4, 2020 | - | Jul 22, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
XYNGARI | acne | Phase 3 | 2025-05-14 | statistically significant results of its three co-primary endpoints at all time points Read More | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical Read More | |
XYNGARI | acne | Phase 3 | 2025-05-14 | statistically significant results of its three co-primary endpoints at all time points Read More | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical Read More | |
XYNGARI | acne | Phase 3 | 2025-05-14 | statistically significant results of its three co-primary endpoints at all time points Read More | Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DRMA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DRMA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DRMA▲ +14.8%today
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
Dermata Therapeutics has announced that preorders for its Tome Foundational Treatment are now available, with shipping set to begin on August 25, 2026. This product, designed for skin renewal, will retail at $178 and includes a unique application process. The company aims to fill a gap in the skincare market with this innovative offering.
Read more →DRMADermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics has announced a private placement to raise $3.4 million, with the potential for an additional $6.7 million from warrant exercises. The offering includes shares and warrants priced at $1.46 each, with participation from company insiders. Proceeds will be used for general corporate purposes, including the launch of new skincare products. The closing is expected on August 18, 2026, pending customary conditions.
Read more →DRMA▲ +27.8%on this news· ran to +45% by day 1shared move
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Dermata Therapeutics announced a corporate update highlighting its transition to a direct-to-consumer skincare company. The company plans to launch its first product, Tome Foundational Treatment, on August 25, 2026, following a successful presence at the Be+Well Beauty and Wellness Show. Financial results showed a decrease in cash reserves and increased operational costs, but Dermata remains optimistic about future growth and product development.
Read more →DRMA▲ +6.4%on this news
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
Dermata Therapeutics has announced the commercial launch date for its Tome Foundational Treatment, set for August 25, 2026. This marks the company's first direct-to-consumer skincare product, aimed at providing professional-grade solutions at home. The treatment utilizes proprietary Bioneedle technology and is designed to simplify skincare routines while addressing common skin concerns.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to
Dermata Therapeutics reported financial results for the first quarter of 2026, highlighting a strategic pivot to the direct-to-consumer skincare market with the launch of their Tome Skincare brand. The company raised $2 million in ATM financing and is preparing for the mid-2026 launch of its initial product, the Foundational Treatment. Despite a decrease in total cash and an ongoing net loss, management remains optimistic about their new direction and product strategies aimed at delivering value to consumers and shareholders.
Read more →DRMA▼ -13.9%on this news
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Dermata Therapeutics has announced a strategic pivot towards direct-to-consumer skincare products, launching its brand Tome. The company plans to introduce its Foundational Treatment in mid-2026, supported by a recent $4.125 million financing round. Dermata is also developing a Clearing Treatment for acne, aiming to simplify skincare routines. Despite positive developments, the company has withdrawn its previous drug application for XYNGARI.
Read more →DRMA▼ -5.7%on this news
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Dermata Therapeutics has received a patent grant from the Australian Patent Office for its Spongillatechnology, aimed at treating acne. This patent follows a similar grant in the U.S. and supports the upcoming launch of a once-weekly OTC acne treatment system in mid-2026. The company aims to address significant unmet needs in dermatology with this innovative approach.
Read more →DRMA▲ +22.6%on this news
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dermata Therapeutics has successfully closed a private placement, raising $4.1 million upfront, with potential additional proceeds of $8.3 million from warrants. The offering included shares of common stock and warrants, priced at $2.04 each. The funds will be used for general corporate purposes, including the development of a new OTC acne kit set to launch in 2026.
Read more →DRMA▲ +16.2%on this newsshared move
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules $4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exer
Dermata Therapeutics has announced a private placement aimed at raising up to $12.4 million. This includes $4.1 million upfront, with an additional $8.3 million contingent upon the exercise of warrants. The proceeds will be used primarily for research and the launch of an over-the-counter acne kit scheduled for mid-2026. Insider participation in this offering suggests confidence in the company's future prospects, though uncertainties remain regarding the exercise of warrants and market conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata p
Dermata Therapeutics announced a strategic pivot focusing on over-the-counter (OTC) skincare solutions, aiming to launch its first product, an acne treatment kit, by mid-2026. This move follows positive results from its XYNGARI Phase 3 STAR-1 clinical trial for moderate-to-severe acne, reinforcing the efficacy of its Spongilla technology. The company reported a financial increase with $4.7 million in cash, although it continues to experience operational losses. Dermata is currently developing branding strategies for its new OTC product line while planning to sell directly to consumers and professionals.
Read more →DRMA▲ +5.5%on this news
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - Dermata announced additional positive data from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinica
Dermata Therapeutics has announced encouraging results from its XYNGARI Phase 3 STAR-1 clinical trial, which successfully met its three co-primary endpoints for treating moderate-to-severe acne. The company reported a gross fundraising of $8.8 million during the first half of 2025, bolstering its financial capacity to support operations through mid-2026. With positive early data indicating effectiveness as soon as four weeks, Dermata is optimistic about the potential benefits of its Spongilla technology in acne treatment.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical
Dermata Therapeutics reported encouraging results from its XYNGARI Phase 3 STAR-1 trial, meeting all co-primary endpoints for acne treatment. The company also secured $8.8 million in funding and signed a Clinical Trial Collaboration Agreement with Revance Therapeutics to research DMT410. The upcoming second Phase 3 trial for XYNGARI is set to start soon. Overall, Dermata's advancements demonstrate significant progress in its medical skin disease treatment initiatives.
Read more →DRMADermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in P
Dermata Therapeutics announced that its XYNGARI Phase 3 trial yielded statistically significant results in separating from placebo after just four treatments. In particular, patients showed improvement in inflammatory and non-inflammatory lesion counts as early as week 4. The once-weekly topical treatment could position XYNGARI as a competitive option for patients with moderate-to-severe acne. The company plans to use these positive results to support a future new drug application with the FDA.
Read more →DRMA▲ +5.2%on this news
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
Dermata Therapeutics announced positive topline results from its Phase 3 trial of XYNGARI™, a once-weekly topical treatment for moderate-to-severe acne. The trial met all primary endpoints, showing significant efficacy compared to placebo. The product demonstrated a favorable safety profile, with minimal adverse events reported. Dermata plans to initiate a second Phase 3 trial in late 2025.
Read more →DRMA▲ +5.2%on this newsshared move
Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics has announced the exercise of warrants, resulting in $6.2 million in gross proceeds to support its ongoing research and development efforts. The company's action includes immediate warrant exercises at a reduced price, leading to the issuance of new Series A and B warrants contingent on shareholder approval. The funds raised will be utilized for corporate purposes, including clinical trials for its product candidates. The offering is set to close on March 28, 2025, pending customary conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results - Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical tri
Dermata Therapeutics has provided a corporate update alongside its year-end 2024 financial results. The company anticipates announcing topline results from its Phase 3 STAR-1 clinical trial for moderate-to-severe acne by the end of March 2025, following the successful enrollment of participants. Additionally, Dermata entered a collaboration agreement with Revance Therapeutics to advance their DMT410 treatment for hyperhidrosis. While the company raised significant funds, it reported a decrease in cash reserves and elevated research expenditures over the past year.
Read more →DRMADermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Dermata Therapeutics has announced the completion of the last patient visit in its pivotal Phase 3 STAR-1 clinical trial for XYNGARI™, a novel topical treatment for moderate-to-severe acne. The trial enrolled 520 patients across the U.S. and Latin America, with topline results expected by the end of March 2025. XYNGARI™ aims to provide a more effective and convenient alternative to existing acne therapies.
Read more →DRMA▼ -16.5%on this news
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE /
Dermata Therapeutics has announced a private placement of 2,007,880 shares of common stock priced at $1.27 per share, aiming to raise approximately $2.55 million. The funds will be utilized for general corporate purposes, which include ongoing research, clinical trials, and potential acquisitions. Company insiders, including key executives, are participating in this offering, highlighting their commitment to the company's future. The offering is under Nasdaq rules and is subject to certain customary closing conditions.
Read more →DRMADERMATA AND REVANCE ENTER CLINICAL TRIAL COLLABORATION AGREEMENT FOR THE TOPICAL APPLICATION OF XYNGARI WITH DAXXIFY - The Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari wit
Dermata Therapeutics and Revance Therapeutics have announced a collaboration to begin a Phase 2a clinical trial for the combination of Xyngari and Daxxify, targeting primary axillary hyperhidrosis. This trial, involving approximately 48 patients, will evaluate the safety and efficacy of the topical treatment compared to a placebo. If successful, there are plans to explore additional indications for this innovative needle-free method of botulinum toxin delivery. The companies believe this collaboration could provide a significant advancement in treatment options for patients.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial
Dermata Therapeutics has provided a corporate update alongside its financial results for Q3 2024. The company is close to completing enrollment in its DMT310 Phase 3 STAR-1 clinical trial for moderate-to-severe acne and expects to report topline results in early 2025. Dermata raised $5.1 million recently, which will help sustain operations into the second quarter of 2025. However, the company also reported a net loss and a decrease in cash reserves compared to the previous year.
Read more →DRMA▲ +46.8%on this news
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE /
Dermata Therapeutics has announced a $3.5 million private placement priced at-the-market under Nasdaq rules. The offering includes 1,912,569 shares of common stock and accompanying warrants, which will be exercisable upon issuance. Proceeds from the offering will be utilized for general corporate purposes, including ongoing research and clinical trials. The close of the placement is anticipated around September 17, 2024, pending customary closing conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - - Dermata
Dermata Therapeutics has reported a significant milestone in its DMT310 Phase 3 STAR-1 clinical trial, having enrolled over 50% of patients. The company also raised $2.3 million in net proceeds in the second quarter of 2024, although it saw a decrease in cash reserves compared to the previous period. The DMT310 product is aimed at addressing acne with a once-weekly topical application, while discussions continue regarding potential partnerships for its DMT410 program.
Read more →DRMA▼ -19.2%on this news· ran to -30% by day 3
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Dermata Therapeutics has announced the exercise of outstanding warrants, generating approximately $2.66 million in gross proceeds. This exercise involves the issuance of new warrants at a reduced exercise price, aimed at supporting the company's operations and development initiatives. The funds will be allocated to ongoing research, clinical trials, and the acquisition of synergistic companies. The transaction's closing is anticipated on or around May 21, 2024, pending customary closing conditions.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata contin
Dermata Therapeutics provided a corporate update and financial results for Q1 2024, highlighting the progress of its DMT310 Phase 3 clinical trial for acne, which remains on track for enrollment completion by the end of 2024. The company also reported receiving a Japanese patent for its DMT410 program and is actively seeking partnership opportunities for this botulinum toxin treatment. Financially, Dermata noted a decline in cash reserves and a net loss of $3.1 million during the quarter. The company is optimistic about DMT310's potential to be a leading acne treatment if successful in trials.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results - Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - - Raised $9.1
Dermata Therapeutics announced a corporate update and disclosed its financial results for 2023, highlighting the initiation of the DMT310 Phase 3 clinical trial for treating acne. The company successfully raised $9.1 million in gross proceeds through three financings during the year. Additionally, Dermata received a Japanese patent for DMT410, aimed at treating hyperhidrosis, adding potential value to its product pipeline. The company aims to complete enrollment for the STAR-1 trial by late 2024, with topline results expected in early 2025.
Read more →DRMA▲ +6.7%on this news· ran to +21% by day 3
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE /
Dermata Therapeutics, Inc. has announced the exercise of outstanding warrants for gross proceeds of $2.26 million, priced at $0.6511 per share. The funds are intended for general corporate purposes, including ongoing research, clinical trials, and development of new technologies. New warrants will be issued alongside the exercise of the existing ones, which are also connected to additional future developments in the company's product pipeline. The closing of this transaction is anticipated on or around November 20, 2023, subject to customary conditions.
Read more →DRMA▲ +8.6%on this news
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feedb
Dermata Therapeutics has announced a corporate update and reported its financial results for the third quarter of 2023. The company raised $6.8 million from two financing rounds and received positive FDA feedback regarding its End of Phase 2 meeting for the DMT310 program. Dermata is preparing to initiate its Phase 3 STAR-1 clinical trial for acne, following the approval of amended protocols that include additional FDA recommendations. The company's current cash position is adequate to sustain operations through the second quarter of 2024.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results - Raised an aggregate of $6.8 million in gross proceeds from two financings completed in 1H 2023 - - Received positive feed
Dermata Therapeutics provided an update on its recent corporate progress and reported financial results for Q2 2023. The company raised $6.8 million through two financings, aiding its operations into 2024. Positive feedback from the FDA regarding the End of Phase 2 meeting has set the stage for the anticipated Phase 3 clinical trial of DMT310, expected to begin in the latter half of 2023. Additionally, Dermata is pursuing partnerships for its second product candidate, DMT410, aimed at delivering botulinum toxin topically.
Read more →DRMADermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules San Diego, CA/ ACCESSWIRE/
Dermata Therapeutics has announced a registered direct offering of 800,877 shares at $2.285 per share, aiming to raise approximately $1.8 million. The company plans to use the proceeds to advance its ongoing research and development of treatments for skin diseases. The offering includes concurrent private placement warrants and is expected to close by May 26, 2023. H.C. Wainwright & Co. is the placement agent for this financing initiative.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results - Dermata raised $5 million gross proceeds from a public offering in March 2023 - - Dermata submitted an End of Phase 2 meet
Dermata Therapeutics has reported significant progress in its corporate activities and first-quarter financial results. The company raised $5 million from a public offering and submitted an End of Phase 2 meeting package to the FDA regarding its acne treatment candidate, DMT310. The FDA has approved the company's chemistry, manufacturing, and control procedures to support moving into Phase 3 studies. The company is optimistic about moving forward but acknowledges potential uncertainties related to regulatory and operational issues.
Read more →DRMADermata Therapeutics Announces Pricing of $5.0 Million Public Offering San Diego, CA/ ACCESSWIRE/
Dermata Therapeutics announced the pricing of a public offering of approximately $5 million, involving 1,618,123 shares of common stock and accompanying warrants. The closing of the offering is anticipated around March 20, 2023, pending customary conditions. The funds raised will be used for general corporate purposes, including research and the development of new technologies. Changes have also been made to existing warrants, reducing their exercise price to $2.82 per share.
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results - End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 - - Initiation of DMT310 Phase 3 cl
Dermata Therapeutics has provided a corporate update highlighting progress in its DMT310 and DMT410 programs. The company anticipates conducting an end of Phase 2 meeting with the FDA for DMT310 in Q2 2023, leading towards a Phase 3 clinical trial in the second half of 2023. Despite a decrease in cash reserves from $10.8 million to $6.2 million since last year, Dermata remains focused on advancing its innovative treatment options for moderate-to-severe acne and hyperhidrosis.
Read more →DRMADermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea - Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not me
drma_ex991.htm EXHIBIT 99.1 Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea - Data supportive of DMT310 as a treatment for inflammatory skin diseases, but rosacea study did not meet primary endpoints - - DMT3
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results - DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3
drma_ex991.htm EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results - DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Dermata completes a $5.0 million private placement financing in April 2022 - - DMT310 Phase 2 rosacea trial topline resul
docrijz0.htm EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Dermata completes a $5.0 million private placement financing in April 2022 - - DMT310 Phase 2 rosacea trial topline results expected in the second half
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 202
drma_ex991.htm EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA, May 16, 202
Read more →DRMADermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
drma_ex991.htm EXHIBIT 99.1 Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA, April 21, 2022 -- Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq: DRMA and DRMAW), a clinical-stage biotechnology c
Read more →DRMADermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial
drma_ex991.htm EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topli
Read more →DRMADermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
PRESS RELEASE DATED JANUARY 13, 2022 drma_ex991.htm EXHIBIT 99.1 Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors SAN DIEGO, CA, January 13, 2022 - Dermata Therapeutics, Inc. (Nasdaq: DRMA) ("Dermata," or the "Company"), a clinical-stage biotechn
Read more →DRMADermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions - Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - - Duration of
drma_ex991.htm EXHIBIT 99.1 Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions - Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - - Duration of effect lasted approximately
Read more →DRMADermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed
drma_ex991.htm EXHIBIT 99.1 Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update - Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initi
Read more →DRMADermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT
Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Completed oversubscribed $18 million Initial Public Offering - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis
Read more →DRMADermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer SAN DIEGO, September 1, 2021 Dermata Therapeutics, Inc. ( Dermata, or the Company ) (Nasdaq: DRMA; DMRAW), a clinical-stage biopharmaceutical company focused on
Read more →DRMADermata Therapeutics Announces Initiation of a Phase 1b Trial of the Once-Weekly Topical Application of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
SAN DIEGO, March 30, 2021 /PRNewswire/ -- Dermata Therapeutics, Inc., a privately held biotechnology company, announced today that it has dosed its first patient in a Phase 1b trial of DMT310 for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candid
Read more →Competitive Position
How DRMA ranks across every disease it competes inCompetitive Position is a premium feature
See how DRMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial